Patents Examined by Jason Sims
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8906929
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 9, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Combined fibrinolytic and antimicrobial catheter and uses thereof
    Patent number: 8895047
    Abstract: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: November 25, 2014
    Assignee: Arrow International, Inc.
    Inventors: Nisha Gupta, Joel Rosenblatt, Daniel J. Spangler
  • Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses
    Patent number: 8889692
    Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 18, 2014
    Assignee: AstraZeneca AB
    Inventors: Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
  • Magnetic nanomedicine for inhibiting/treating human prostate cancer
    Patent number: 8889192
    Abstract: The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: November 18, 2014
    Assignee: Chang Gung University
    Inventors: Mu-Yi Hua, Hung-Wei Yang, Cheng-Keng Chuang, See-Tong Pang, Hao-Li Liu, Rung-Ywan Tsai, Kun-Lung Chuang
  • Treatment of lupus nephritis using laquinimod
    Patent number: 8889661
    Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: November 18, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Asi Haviv, Nora Tarcic
  • Method and apparatus for analysis of tissue microarrays
    Patent number: 8880351
    Abstract: The present techniques include methods and systems for finding correspondences between tissue spots in tissue microarray serial sections belonging to the same recipient block. The present techniques may also be used to relate individual tissue cores to clinical information. Using either a whole slide image or the relative x-y coordinates of the tissue spots on the slide, individual tissue spots in different tissue microarrays may be linked to one another and their clinical information.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: November 4, 2014
    Assignee: General Electric Company
    Inventors: Ali Can, Michael John Gerdes, Musodiq Olatayo Bello, Xiaodong Tao, Maximilian Seel
  • Methotrexate adjuvants to reduce toxicity and methods for using the same
    Patent number: 8853227
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: October 7, 2014
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Compounds useful as inhibitors of ATR kinase
    Patent number: 8853217
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: October 7, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Pierre-Henri Storck, John Studley, Francoise Yvonne Theodora Marie Pierard
  • Hydrogels with network defects enhanced by nanoparticle incorporation
    Patent number: 8852614
    Abstract: Compositions and methods are provided for the manufacture and use of hydrogels with increased permeability to macromolecules with minimum loss of matrix mechanical strength and prepolymer viscosity for patternability. The hydrogels of the invention are formed from a prepolymer, which is polymerized in the presence of hydrophobic nanoparticles. In some embodiments of the invention cells are present during polymerization, and are encapsulated by the hydrogel. A high interfacial energy between the hydrophobic substrate and the aqueous polymerizing solution disrupts the hydrogel network structure, leading to network defects that increase permeability without loss of patternability.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: October 7, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Curtis W. Frank, Won Jae Lee, Nam-Joon Cho, Jeffrey S. Glenn
  • Neuronal pain pathway modulators
    Patent number: 8846742
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: September 30, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • Small molecules modulator of epigenetic regulation and their therapeutic applications
    Patent number: 8846932
    Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 30, 2014
    Assignee: University of Southern California
    Inventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos A. Petasis
  • Method for ameliorating pruritus
    Patent number: 8846039
    Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: September 30, 2014
    Assignee: Asan Laboratories Company (Cayman), Limited
    Inventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
  • N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
    Patent number: 8846675
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: September 30, 2014
    Assignee: Cymabay Therapeutics, Inc.
    Inventors: Jingyuan Ma, Christopher J. Rabbat, Jiangao Song, Xin Chen, Imad Nashashibi, Zuchun Zhao, Aaron Novack, Dong Fang Shi, Peng Cheng, Yan Zhu, Alison Murphy
  • Azaindazoles as kinase inhibitors and use thereof
    Patent number: 8846673
    Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4 are as defined herein.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: September 30, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Bin Jiang, Zhonghui Lu
  • Peptidomimetic sulfamide compounds and antiviral uses thereof
    Patent number: 8840878
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 23, 2014
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Use of gene expression profiling to predict survival in cancer patient
    Patent number: 8843320
    Abstract: Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: September 23, 2014
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
  • Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
    Patent number: 8841287
    Abstract: Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: September 23, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Hui Cai, Frank Chavez, Paul J. Dunford, Andrew J. Greenspan, Steven P. Meduna, Jorge A. Quiroz, Brad M. Savall, Kevin L. Tays, Robin L. Thurmond, Jianmei Wei, Ronald L. Wolin, Xiaohu Zhang
  • Absolute PCR quantification
    Patent number: 8831887
    Abstract: The present application provides methods and devices for absolute quantification of polymerase chain reaction target nucleic acids. In particular, the methods and devices of the present application provide for splitting a nucleic acid sample to be analyzed into small, isolated volumes, conducting the method of polymerase chain reaction (PCR) on said volumes, detecting PCR amplification products, analyzing said detected PCR amplification products, performing absolute quantification of the PCR target and presenting said quantification results.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: September 9, 2014
    Assignee: The Research Foundation for the State University of New York
    Inventors: Vera Gorfinkel, Boris Gorbovitski
  • Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
    Patent number: 8822462
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: September 2, 2014
    Assignee: Emory University
    Inventors: Stephen F. Traynelis, Dennis C. Liotta, Rose M. Santangelo, Ethel C. Garnier
  • Hair care compositions
    Patent number: 8815225
    Abstract: The invention relates to hair care compositions comprising an effective amount of a condensation polymer having at least one, optionally quarternized or protonated, dialkylamide end-group connected through the polymer backbone to a unit derived from an alkylamide, the connection comprising at least one ester linkage.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: August 26, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Raphael Beumer, Franciscus Derks, Christine Mendrok